Lipoprotein(a) in Atherosclerotic Diseases: From Pathophysiology to Diagnosis and Treatment
Molecules · 18.01.2023 · 28 (3) · 969
DOI: 10.3390/molecules28030969 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Molecules, online erschienen am 18.01.2023. Verfasst von Stamatios Lampsas und 14 weiteren Autor:innen. Beteiligte Einrichtung: 3rd Department of Cardiology, National and Kapodistrian University of Athens, Medical School, Sotiria Chest Disease Hospital, 11527 Athens, Greece. Hauptthemen laut MEDLINE: Atherosclerosis, Hydroxymethylglutaryl-CoA Reductase Inhibitors, Cardiovascular Diseases. Die Arbeit wurde bisher 167-mal zitiert (Crossref) und nennt 272 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Lipoprotein(a) (Lp(a)) is a low-density lipoprotein (LDL) cholesterol-like particle bound to apolipoprotein(a). Increased Lp(a) levels are an independent, heritable causal risk factor for atherosclerotic cardiovascular disease (ASCVD) as they are largely determined by variations in the Lp(a) gene (LPA) locus encoding apo(a). Lp(a) is the preferential lipoprotein carrier for oxidized phospholipids (OxPL), and its role adversely affects vascular inflammation, atherosclerotic lesions, endothelial function and thrombogenicity, which pathophysiologically leads to cardiovascular (CV) events. Despite this crucial role of Lp(a), its measurement lacks a globally unified method, and, between different laboratories, results need standardization. Standard antilipidemic therapies, such as statins, fibrates and ezetimibe, have a mediocre effect on Lp(a) levels, although it is not yet clear whether such treatments can affect CV events and prognosis. This narrative review aims to summarize knowledge regarding the mechanisms mediating the effect of Lp(a) on inflammation, atherosclerosis and thrombosis and discuss current diagnostic and therapeutic potentials.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- 3rd Department of Cardiology, National and Kapodistrian University of Athens, Medical School, Sotiria Chest Disease Hospital, 11527 Athens, Greece.
- 1st Department of Cardiology, National and Kapodistrian University of Athens, Medical School, Hippokration General Hospital, 11527 Athens, Greece.
- Cardiovascular Division, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA.
ORCID-Profile: Stamatios Lampsas, Evangelos Oikonomou, Panteleimon Pantelidis, Stavroula A Paschou, Panagiotis Theofilis
Zitieren
APA
Lampsas, S., Xenou, M., Oikonomou, E., Pantelidis, P., Lysandrou, A., Sarantos, S., Goliopoulou, A., Kalogeras, K., Tsigkou, V., Kalpis, A., Paschou, S. A., Theofilis, P., Vavuranakis, M., Tousoulis, D., & Siasos, G. (2023). Lipoprotein(a) in Atherosclerotic Diseases: From Pathophysiology to Diagnosis and Treatment. Molecules, 28(3), 969. https://doi.org/10.3390/molecules28030969
Vancouver
Lampsas S, Xenou M, Oikonomou E, Pantelidis P, Lysandrou A, Sarantos S, et al. Lipoprotein(a) in Atherosclerotic Diseases: From Pathophysiology to Diagnosis and Treatment. Molecules. 2023;28(3):969. doi:10.3390/molecules28030969
BibTeX
@article{Lampsas2023,
author = {Lampsas, Stamatios and Xenou, Maria and Oikonomou, Evangelos and Pantelidis, Panteleimon and Lysandrou, Antonios and Sarantos, Savvas and Goliopoulou, Athina and Kalogeras, Konstantinos and Tsigkou, Vasiliki and Kalpis, Athanasios and Paschou, Stavroula A and Theofilis, Panagiotis and Vavuranakis, Manolis and Tousoulis, Dimitris and Siasos, Gerasimos},
title = {Lipoprotein(a) in Atherosclerotic Diseases: From Pathophysiology to Diagnosis and Treatment},
journal = {Molecules},
year = {2023},
volume = {28},
number = {3},
pages = {969},
doi = {10.3390/molecules28030969}
}
EUVIMED